110 results about "Cell toxicity" patented technology

The invention provides a specific sequence nucleic acid molecule and application thereof as a PDRN, and relates to the technical field of biology. A novel nucleic acid molecule with a specific sequence is obtained, and the sequence has certainty, biological activity and stable product quality. The PDRN of the specific sequence does not have cytotoxicity, is high in safety and has a wide application prospect. Moreover, compared with the extracted PDRN, the PDRN with a specific sequence is found for the first time, the product has a remarkable effect of promoting VEGF expression, cell damage can be effectively repaired, and a novel skin-care and repairing functional component is provided for the industries of cosmetics and medicines. The invention further provides a preparation method of the PDRN with the specific sequence, and the preparation method is simple and suitable for popularization, application and industrial production.

The invention discloses a method for inhibiting production of vomitoxin from bacillus cereus, which is characterized in that isoleucine is added into a substance needing to inhibit production of vomitoxin from bacillus cereus, preferably 5-20mM of isoleucine is added. According to the present invention, the content of the toxin is detected through the liquid chromatography-mass spectrometry, and the cytotoxicity experiment verification results show that the isoleucine can significantly inhibit the synthesis of the vomitoxin of the bacillus cereus in the culture medium and the matrix, and can effectively reduce the toxic effect of the toxin on HeLa cells; the invention provides a safe and efficient biological control means which is suitable for various food systems such as starch food, dairy products, meat products and the like. Isoleucine can be used as a novel non-toxic and harmless food additive and is low in cost; the use method is simple, the output of vomitoxin can be reduced by directly adding a trace amount of isoleucine, and the food flavor is not affected.

The invention relates to composite hydrogel for tissue repair as well as a preparation method and application of the composite hydrogel. The composite hydrogel is prepared from a methacrylated acellular matrix, nano clay (LAP), a photoinitiator, carboxymethyl chitosan (CMCS) and water. The acellular matrix is modified through methylacryloylation, and a polymer network is reinforced by combining nano-clay, so that the mechanical strength is improved; and carboxymethyl chitosan adjusts the degradation rate, constructs a pore structure and endows antibacterial and anti-inflammatory functions. The preparation method comprises the following steps: dissolving the methacrylated acellular matrix in the PBS containing the photoinitiator, dissolving the carboxymethyl chitosan in ultrapure water, mixing, and carrying out illumination cross-linking curing. When the composite hydrogel is applied to small intestine tissue engineering, a small intestine defect part can be filled with the composite hydrogel, photo-crosslinking curing is performed to form a stent, the degradation period is matched with the small intestine regeneration period, and the antibacterial rate is gt; the cell toxicity is 0 level, a good microenvironment can be provided for cells, tissue repair can be promoted, and the compound can also be used for preparing pharmaceutical compositions for treating small intestine related diseases.

This document provides methods and materials involved in treating cancer. For example, methods and materials for modulating (e.g., increasing or decreasing) an interleukin-1 (IL-1) signaling pathway (e.g., an IL-1βsignaling pathway) during an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) are provided. In some cases, one or more inhibitors of an interleukin-1 receptor antagonist (IL-1RA) polypeptide can be used to increasing IL-1 signaling (e.g., to reduce immunosuppression of the administered cells). In some cases, CAR T cells having a reduced level of an interleukin 1 receptor, type I (IL-1R1) polypeptide can have decreased IL-1 signaling (e.g., to reduce T cell toxicity associated with the administered cells).

The invention discloses a tetrandrine ferulate and its application in the preparation of a medicament for treating pulmonary fibrosis. The pharmacological effects of tetrandrine and ferulic acid, as well as those after salification, are studied. It is found that both have an anti-pulmonary fibrosis effect, and the two can be used in combination to synergistically exert a more excellent anti-pulmonary fibrosis efficacy. At the same time, the solubility of tetrandrine can also be increased. This has not been reported in existing literature. The tetrandrine ferulate of the present invention has lower cytotoxicity, and the cell viability of normal human liver cells LO-2 and human embryonic fibroblasts MRC-5 is higher than that of tetrandrine, which alleviates the burden of liver and lungs to a certain extent and has good safety.

The invention belongs to the technical field of fluorescent probes and supramolecules, and particularly relates to an organic small molecule fluorescent probe for lithium ion detection as well as a synthesis method and application of the organic small molecule fluorescent probe. Aiming at the problems that an existing fluorescent probe for identifying Li < + > is easily influenced by pH and interfered by coexisting metal ions, and is poor in water solubility, low in sensitivity, poor in selectivity and the like, the crown ether fluorescent molecular probe for detecting the lithium ions is 4-aza-12-crown-4-ether-7-nitrobenzofuran; the compound is prepared from 4-chloro-7-nitrobenzofuran and aza 12-crown-4-ether in a substitution manner. The fluorescent probe has the advantages that 1) the structure is simple, the preparation is easy, and excitation and emission wavelengths are in a visible light region; 2) good water solubility is achieved; 3) the material has good selectivity on lithium ions; 4) the method has the advantages of high sensitivity, quick response and the like in lithium ion detection, and can be used for in-situ-real-time detection of lithium ions; and (5) the cell toxicity is low, and the biocompatibility is good.

The present disclosure provides compositions and methods for inserting heterologous payload sequences into a target-site in a host cell genome. The compositions and methods use non-LTR retrotransposon reverse transcriptase proteins that bind template RNAs comprising a payload sequence that encodes a protein or regulatory RNA. The template RNA can comprise modified uridines that are not cleavable by a ribozyme. The incorporation of modified uridines increases the efficiency of integration and expression of the payload sequence and decreases cellular toxicity.

The invention discloses a film-embedded conjugated oligomeric electrolyte based on a natural product, and the structure of the film-embedded conjugated oligomeric electrolyte takes a natural polyphenol compound as a conjugated skeleton part, so that the overall biocompatibility of molecules is improved, and the toxicity is reduced; alkyl chains with different lengths or numbers are used as side chain parts to adjust the compatibility with a cell membrane and promote the membrane embedding and retention of molecules, and the alkyl chains can disturb the phospholipid arrangement of the cell membrane and increase the membrane permeability after the molecules are embedded into the membrane; a positively charged group is used as an end group part, and a negatively charged cell membrane is anchored through electrostatic attraction, so that the local molecular concentration is improved. The cell membrane is modified by the embedded membrane conjugated oligomeric electrolyte derived from the natural product, so that the permeability of the cell membrane is improved, the cytotoxicity is reduced, and the catalytic efficiency of cells is improved. The cell membrane is modified by the embedded membrane conjugated oligomeric electrolyte derived from the natural product, so that the permeability of the cell membrane is improved, the cytotoxicity is reduced, and the catalytic efficiency of cells is improved.

This invention provides specific sequence nucleic acid molecules and their applications as PDRNs, relating to the field of biotechnology. This invention yields novel specific sequence nucleic acid molecules with deterministic sequences, stable biological activity, and stable product quality. The PDRNs with these specific sequences are non-cytotoxic, exhibit high safety, and have broad application prospects. Furthermore, this invention is the first to discover that specific sequence PDRNs, compared to extracted PDRNs, significantly promote VEGF expression and effectively repair cell damage, providing a novel skincare and repair ingredient for the cosmetics and pharmaceutical industries. This invention also provides a simple method for preparing specific sequence PDRNs, suitable for widespread application and industrial production.

Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula —[CH2]n— with n=0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.

The application relates to a lysis module for E. coli autolysis, a system and application thereof, relates to the field of E. coli autolysis, and the lysis module is SP-lysozyme-SsrA, the SP is a nucleotide sequence for coding a signal peptide, the amino acid sequence of the SsrA degradation label is SEQ ID NO:8, the nucleotide sequence of the lysozyme is SEQ ID NO:1, the SP is fused at the N-terminal of the lysozyme, and the SsrA is fused at the C-terminal of the lysozyme. By adopting a simpler and more efficient mode to assist lysozyme in the cytoplasm to enter the periplasmic space, the number of lysis modules is reduced to reduce the metabolic burden caused to host cells; meanwhile, the problem of lysis module leakage expression is solved, cell toxicity is reduced, and the biomass of host cells and the yield of target proteins are improved.

This invention belongs to the field of pharmaceutical technology and discloses small organic molecules for reducing copper overload toxicity and their applications. Specifically, it discloses four small organic molecules for reducing copper overload toxicity and methods for doing so. These four small organic molecules are not copper chelators and do not reduce intracellular copper levels, thus not affecting the activity of copper-related enzymes. Furthermore, these four small organic molecules are not copper ion transporters and do not transport copper into cells, thus not exacerbating the cytotoxicity of copper overload.

The application relates to a preparation method and application method of a mesenchymal stem cell protective agent composition, and relates to the technical field of stem cell treatment, in particular to a protective agent composition, a preparation technology of the protective agent composition and an application technology of the protective agent composition in mesenchymal stem cell treatment. The application solves the problems of insufficient cell stemness maintenance, complex formula or cell toxicity in the existing mesenchymal stem cell cryopreservation. The protective agent composition prepared by the preparation method comprises a deferoxamine pretreatment protective agent and a sodium lactate Ringer injection storage solution. The application method inhibits low-temperature-induced ferroptosis through DFO pretreatment, so that the mesenchymal stem cells can still maintain the multi-directional differentiation potential, the immunoregulatory function and the proliferation ability after being treated at 4 DEG C for 24-48 hours, the serum or complex nutritional ingredients do not need to be added, and the protective agent composition has the advantages of clear composition, high safety, simple operation and the like. The application is suitable for the fields of stem cell treatment, regenerative medicine, pet medical treatment and the like.

The invention belongs to the technical field of synthetic biology and fermentation engineering, and discloses an engineering bacterium for producing Indigoidine based on membrane vesicle engineering reinforced corynebacterium glutamicum and application of the engineering bacterium. According to the invention, the ncp1 gene of corynebacterium glutamicum is knocked out through a CRISPR-Cas12a gene editing technology, connection between cell walls and cell membranes is relieved, and a chassis strain of high-yield extracellular membrane vesicles (OMVs) is constructed; meanwhile, a recombinant expression vector is introduced, indigo synthetase BpsA is positioned and displayed on membrane vesicles by utilizing PorB anchoring protein, and activating enzyme Sfp is co-expressed. In fermentation production, a staged feeding and IPTG (isopropyl-beta-d-thiogalactoside) and Tween-80 dual induction strategy is adopted to promote thalli to express zymoprotein and release a large number of membrane vesicles at the same time. According to the method, the membrane vesicles are used as an extracellular microreactor, so that the'simultaneous synthesis and secretion 'of the indissolvable indigo is realized, the problems of cytotoxicity and metabolic inhibition caused by intracellular precipitation of the product are effectively solved, and the yield and extraction efficiency of the indigo are remarkably improved.

The invention discloses application of an aromatic hydrocarbon receptor stimulant in preparation of a medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation, and belongs to the field of biological medicine. According to the present invention, with the PAS-B structural domain of the AHR as the target, the virtual screening technology, the target verification test and the weaned piglet diarrhea pharmacodynamic evaluation test are performed to determine the arctigenin as the AHR strong agonist and the anti-inflammatory drug, and the arctigenin has the good treatment effect on the weaned piglet diarrhea. Experimental results show that 10 mg / kg of arctigenin can significantly relieve diarrhea and hemafecia symptoms of weaned piglets, reduce the content of inflammatory factors in serum and intestinal tissues and improve the intestinal structure of weaned piglets, has no significant cytotoxicity, hepatorenal toxicity and intestinal epithelial cell growth inhibition effect, and can be used for preparing a feed additive for weaned piglets. The compound can be used for preparing medicines for treating diarrhea of weaned piglets. The invention provides a new raw material medicine for treating diarrhea of weaned piglets, and has great economic value and wide application prospect.

The application discloses preparation and application of a kind of antimony tungstate material with catalytic Fenton reaction activity, the molecular formula of the antimony tungstate material is H 11 [Ln2Sb2W7O 23 (OH)(DMF)2(SbW9O 33 )2]·xH2O, abbreviated as 1-Ln, wherein Ln=Dy, Ho, Er, Tm, Y, Yb or Lu;DMF=N or N-dimethylformamide;The crystal structure of the antimony tungstate material is that two three-defect {B-alpha-SbW9O 33} units sandwich one four-core heterometallic cluster {Sb2Ln2O 10 (DMF)2} and one {W7O 29 (OH)} cluster unit to form a high 1.9nm capsule-like isolated cluster structure, which has good water solubility and stability under physiological conditions.The antimony tungstate material with catalytic Fenton reaction activity can generate a large number of ·OH to kill cancer cells by catalyzing H2O2 decomposition and consuming glutathione through Fenton-like reaction, has high cytotoxicity and selectivity to various cancer cells, can significantly inhibit the growth of tumor in vivo, has small toxic and side effects to normal cells and organs, and can be used as an antitumor drug, applied to the field of biological medicine.

The invention belongs to the field of environmental toxicology and immunology, and particularly relates to an immunotoxicity evaluation method and application thereof. The method comprises the following steps: adding a target pollutant into a culture medium to obtain an exposure culture solution containing the target pollutant, incubating macrophages through the exposure culture solution containing the target pollutant, detecting the macrophages after incubation to obtain results of evaluation indexes, and performing immunotoxicity evaluation based on the results of the evaluation indexes, the target pollutants are chemicals or actual water samples; the evaluation indexes comprise basic cell toxicity, macrophage phagocytic ability and macrophage anti-infection ability. The invention provides a sensitive and reliable immunotoxicity evaluation system, and fills the blank of immunotoxicity evaluation of chemicals, especially raw water. The defects of a traditional concentration method are avoided through a direct exposure method, and the immunotoxicity of the water sample is reflected more truly. The established QSAR model provides a theoretical tool for predicting the immunotoxicity of novel chemicals.

The invention belongs to the field of gene engineering, and relates to a general carrier for blue-green algae genome editing based on an endogenous I-D type CRISPR-Cas system and application of the general carrier. The editing vector contains an artificial blue algae I-D type CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) expression unit (mini-CRISPR). On the basis of the general genome editing carrier, blue-green algae endogenous I-D type Cascade is guided to cut a genome target so as to realize genome editing. Exogenous Cas protein does not need to be expressed in gene editing, so that cytotoxicity is avoided; the method is simple to operate, can realize traceless gene editing, and can be used for various gene editing modes, such as gene knockout, knock-in, point mutation, large fragment knockout, endogenous plasmid elimination and the like.

The application relates to a modified hyaluronic acid antibacterial material, an antibacterial hydrogel and a preparation method and application thereof, relates to the technical field of antibacterial materials, and solves the technical problems that the existing hyaluronic acid-based antibacterial material has weak antibacterial activity, narrow antibacterial spectrum, is easy to rely on oxidation modification, and the hyaluronic acid molecular structure and biological activity are damaged, and the existing nano-silver antibacterial dressing has biological toxicity and poor cell compatibility, and the existing technology is difficult to simultaneously consider the broad-spectrum antibacterial performance, thermal stability, biological compatibility and wound repair capacity. The hyaluronic acid is grafted with quaternary ammonium salt with different quaternary ammonium salt alkyl chain lengths and quaternary ammonium degrees, a hyaluronic acid electrostatic grafting quaternary ammonium salt antibacterial material is prepared, and further crosslinking reaction is carried out on the antibacterial material, a crosslinking agent and glacial acetic acid to obtain an antibacterial hydrogel which has high efficient antibacterial activity, excellent biological compatibility and low cytotoxicity. The application can be applied to the field of hydrogel dressings.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

The present invention relates to a thiobenzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer, comprising the derivative as an active ingredient. The thiobenzimidazole derivative of the present invention exhibits cell toxicity by blocking the cell cycle of a cancer cell and inducing apoptosis when administered to an individual, as the derivative inhibits tubulin polymerization by being activated in the cancer cell, and, thus, the derivative can be used for prevention or treatment of cancer, desirably for prevention or treatment of triple-negative breast cancer.

The present invention discloses a semicarbazide derivative and its preparation method and application, which belongs to the technical field of anti-lung cancer targeted drugs. The semicarbazide derivative of the present invention can inhibit the growth of H1299 cells in a dose-dependent manner, but has little toxicity to normal lung epithelial cells BEAS-2B. The semicarbazide derivative of the present invention can significantly inhibit the cloning of non-small cell lung cancer cells A549 and H1299, so it has a significant inhibitory effect on the proliferation of non-small cell lung cancer. The semicarbazide derivative provided by the present invention can inhibit the protein expression of GPX4 in non-small cell lung cancer A549 cells, and by inhibiting the protein expression of GPX4, promote the ferroptosis of non-small cell lung cancer cells, thereby playing a role in suppressing tumors.

The application discloses application of xanthohumol in preparation of a medicine for resisting Aeromonas hydrophila infection of aquatic animals, and the xanthohumol can inhibit the activity of aerolysin of the Aeromonas hydrophila at a sub-inhibitory concentration, has a significant inhibitory effect on cell toxicity mediated by the aerolysin of the Aeromonas hydrophila, and further constructs an animal model infected by the Aeromonas hydrophila, and finds that the treatment of the xanthohumol can significantly improve the survival rate of the infected animals. The xanthohumol is one of main components of Chinese medicine hop, belongs to isoprenyl flavonoids, has biological functions such as bacteriostasis, anticancer, antioxidation, antiviral and hypoglycemic, and has high safety, and is an ideal medicine raw material or feed additive for preventing and treating the Aeromonas hydrophila infection of the aquatic animals.

The application discloses application of a swertianol derivative in preparation of a glioma treatment drug and belongs to the technical field of medicines. The application finds that the compound has significant inhibitory activity on SF126, T98G, A172, U-87 MG, U251 and various glioma cell lines, and the activity is better than that of temozolomide, a commonly used clinical anti-glioma drug, and the compound has lower toxicity to normal brain cells. The application further provides a preparation method of the compound and a pharmaceutical composition containing the compound, and the pharmaceutical composition can be prepared into injection, tablets and various dosage forms. The application provides a new effective drug selection for the treatment of glioma, has a mature preparation process, various drug dosage forms and a wide clinical application prospect.

A calix[4]arenes of the formula (1a),wherein: Y1, Y2, Y3 and Y4 are selected from hydrogen, halogen, NO2, N3, CN, CHO, COOR′, CONR″2, NR2, triazole moiety and C1-C3-alkyl group, the C1-C3-alkyl group being optionally substituted, Z is a heterocyclic moiety which is selected from the group including of imidazole, benzimidazole, benzothiazole, benzoxazole, purine, tetrazine, oxazole, pyrazole and thiazole, the heterocyclic moiety being optionally substituted, R1 and R2 are selected from hydrogen and C1-C8-alkyl, the C1-C8-alkyl group being optionally substituted, n being an integer between 1 and 4, They exhibit high cytotoxicity against cancer cells.

The present invention relates to a compound for the prevention and / or treatment of neurodegenerative diseases. On one hand, the compound provided by the invention can effectively promote the proliferation of neuronal cells, and on the other hand, the compound has a protection effect on neuronal cell toxicity induced by neurotransmitters such as glutamic acid caused by excessive accumulation of Abeta amyloid protein, so that the effect of treating neurodegenerative diseases is comprehensively exerted; meanwhile, the compound disclosed by the invention has no obvious cytotoxicity. Therefore, the compound has a good application prospect in medicines for preventing or treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and the like. Besides, a parent structure with a key active function on the neurodegenerative disease and an important influencing group in the cynanchum otophyllum extract are defined, the basic structure-function relationship between the compound and the treatment of the neurodegenerative disease is defined, and a sufficient scientific basis is provided for research and development of subsequent related drugs.

Systems and methods consistent with the present invention generally relate to microorganospheres (MOSs), and methods and apparatuses for forming and using MOSs. More particularly, in some embodiments, systems and methods consistent with the invention relate to the methods and apparatuses for forming and using MOSs generated from hepatocytes. MOPSs that are generated from hepatocytes are suitable for testing liver toxicity and drug induced liver injury effects of various agents.

Pyrazolo[1,5-a]pyrimidines are disclosed. These compounds may be useful in the treatment of neurological disorder, including frontotemporal dementia, chronic traumatic encephalopathy, Alzheimer's disease, limbic-predominant age-related TDP-43 encephalopathy, or frontotemporal lobar degeneration. Further, the invention features a method of inhibiting toxicity in a cell related to a protein TDP-43 or C9orf72. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

The invention belongs to the technical field of nano material preparation and application, and discloses a method for liquid-phase stripping of iron oxychloride by cysteine and application. The method comprises the following steps: firstly, preparing blocky iron oxychloride through partial thermal decomposition of ferric chloride hexahydrate; and adding L-cysteine into the iron oxychloride solution, and carrying out ultrasonic treatment at 20-40kHz and 10-40 DEG C for 0.5-6 hours to finally prepare the cysteine-iron oxychloride nano material. The average size of the material is 20-200nm, and the material is strip-shaped, is rich in ferrous iron and oxygen vacancies, and has excellent peroxidase-like activity and Fenton reaction activity. The method is green, simple, convenient and low in cost. The prepared nano material can efficiently catalyze and generate active oxygen species such as hydroxyl free radicals, effectively kills drug-resistant escherichia coli and staphylococcus aureus through multiple mechanisms such as initiation of bacterial lipid peroxidation, DNA degradation and protein leakage consumption, shows good biocompatibility in a cytotoxicity test, and can be used for preparing a drug-resistant nano material. Wide application prospects are realized in the field of antibacterial preparations.

The invention discloses a precise editing method of a gamma-PGA high-yield strain based on CRISPR-Cas9n, and relates to the technical field of high-yield strains. According to the invention, a CRISPR-Cas9n double-nickase system is adopted, and adjacent DNA nicks are generated through the synergistic effect of double sgRNA, so that the non-specific cutting risk is greatly reduced; the double sgRNA targeting design is combined with a homologous recombination template, so that directional editing of key genes is realized, the homologous recombination efficiency reaches 75 + / -5%, and target modification is ensured to be stably integrated into a genome; by virtue of a PEG-mediated protoplast conversion method, the limitation of low efficiency of traditional electrotransfection is overcome, and the CRISPR carrier is rapidly removed in combination with a temperature-sensitive plasmid elimination system, so that cytotoxicity caused by continuous expression is avoided; under optimized fermentation conditions, the gamma-PGA yield of the edited strain reaches 15 + / -2g / L and is increased by 200% compared with that of the original strain.